首页|miRNA在肺动脉高压发病机制中的研究进展

miRNA在肺动脉高压发病机制中的研究进展

扫码查看
肺动脉高压(pulmonary hypertension,PH)是一种以肺血管重塑为特征的进展性疾病.目前对PH的治疗效果仍不理想,迫切需要更好地解读潜在的病理机制以便寻找新的治疗靶点.miRNA(microRNA)是转录后机制中的关键元件,主要通过调节下游靶基因的表达来介导细胞功能.大量的体内和体外研究表明miRNA及其调节因子参与PH发生发展.然而,关于miRNA调控肺血管重塑的机制尚没有统一定论.因此,本文就近年来miRNA在PH中的作用机制进行综述.
Progress of research into the role of miRNA in the pathogenesis of pulmonary hypertension
Pulmonary hypertension(PH)is a progressive disease characterized by pulmonary vascular remodeling.Current treatments for PH remain suboptimal,and there is an urgent need to better decipher the underlying pathomechanisms to identify new therapeutic targets.MicroRNA(miRNA)are key components in the post-transcriptional machinery that mediates cellular functions and mainly act by regulating the expression of downstream target genes.Numerous in vivo and in vitro studies have demonstrated the involvement of miRNA and their regulators in PH development.However,there is no unified model for the mechanism of miRNA's regulation of pulmonary vascular remodeling.Therefore,this article provides a review on the mechanisms of miRNA in PH characterized in recent years.

miRNApulmonary hypertensionpathogenesis

李妍锦、肖丽莹、吴道雄、管蓉、闫春朗、雷雯

展开 >

昆明医科大学第二附属医院呼吸与危重症医学科,昆明 650106

昆明医科大学第二附属医院检验医学科,昆明 650106

miRNA 肺动脉高压 发病机制

云南省教育厅科学研究基金项目昆明医科大学研究生创新基金

2022J01972023S304

2024

中国比较医学杂志
中国实验动物学会,中国医学科学院医学实验动物研究所

中国比较医学杂志

CSTPCD北大核心
影响因子:0.473
ISSN:1671-7856
年,卷(期):2024.34(6)
  • 41